Biotechnology

Dizal Pharmaceutical

Dizal Pharmaceutical released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 252.52 M, actual EPS CNY -0.21

Dizal Pharmaceutical to Release FY2026 Q1 Earnings on April 30 After-Market BJT

Dizal Pharmaceutical to Release FY2025 Earnings on March 31 Pre-Market (BJT), Forecast Revenue CNY 794.2 M, EPS CNY -1.48

Dizal Pharmaceutical released FY2025 earnings on February 27 Pre-Market (BJT), actual revenue CNY 801.14 M (forecast CNY 794.2 M), actual EPS CNY -1.71 (forecast CNY -1.48)

Dizal Pharmaceutical released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 214.83 M, actual EPS CNY -0.3923

Dizal Pharmaceutical released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 586.3 M, actual EPS CNY -1.3213

Dizal Pharmaceutical released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 231.3 M, actual EPS CNY -0.4496

Dizal Pharmaceutical to Release FY2025 Q3 Earnings on October 31 After-Market BJT

Dizal Pharmaceutical released FY2025 Semi-Annual Earnings on August 22 After-Market BJT, actual revenue CNY 355 M, actual EPS CNY -0.87

Dizal Pharmaceutical released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue CNY 195.36 M, actual EPS CNY -0.4116

Dizal Pharmaceutical to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Dizhu Medicine's DZD8586 Receives FDA 'Fast Track' Designation

Dizhe Medicine Shares Rise, Analysts Give Buy Rating

Deezer Medicine Executives Jointly Reduced 443,900 Shares

Dizhu Pharmaceuticals to Unveil Latest Research Findings of Suzhuo and Gaorui in Non-Small Cell Lung Cancer

Dizhu Medicine Executives Announce Concentrated Share Reduction

Dizhe Medicine Conducted a Block Trade

Dizhu Medicine's ZEGFROVY Included in NCCN Non-Small Cell Lung Cancer Guidelines

NMPA Introduces 30-Day Fast-Track Approval for Innovative Drug Clinical Trials

Dizhe Medicine Underwent Block Trades

688192

Dizal (SSE:688192) announced key progress in its non-small cell lung cancer (NSCLC) portfolio, with two oral presentations and a poster at the ASCO 2026 Annual Meeting. The pivotal Phase 3 WU-KONG28 study of ZEGFROVY® (sunvozertinib) will be presented as a Late-Breaking Abstract, showcasing its efficacy in EGFR mutated NSCLC. Additionally, updated data on DZD6008, a fourth-generation EGFR TKI, and findings on golidocitinib in combination with anti-PD-1 therapy will be shared. CEO Dr. Xiaolin Zhang highlighted the significant advancements in their NSCLC pipeline.

prnewswire

12:45 ETDizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026

Dizal's ZEGFROVY® (Sunvozertinib) demonstrated an 81.3% objective response rate as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR PACC or other uncommon mutations. The treatment showed a favorable safety profile, indicating its potential as a promising option. This data was presented at ELCC 2026 and disclosed on March 27, 2026. Dizal is listed on the Shanghai Stock Exchange under the symbol SSE:688192.

Unusual Whales

Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026

Dizal's Phase III WU-KONG28 trial of Zegfrovy (sunvozertinib) for first-line treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations has met its primary endpoint, showing improved progression-free survival compared to platinum-based chemotherapy. The multinational study involved patients from 16 countries, and detailed data will be presented at an upcoming scientific congress. Zegfrovy is already approved for relapsed NSCLC and has received breakthrough therapy designations in the US and China. Dizal plans to engage regulatory authorities for potential new drug applications based on these results.

WorldPharmaceuticals

Dizal’s Phase III NSCLC trial of Zegfrovy meets primary endpoint

Dizal announced positive topline results from its Phase 3 WU-KONG28 study, evaluating ZEGFROVY® (sunvozertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The study demonstrated significant improvement in progression-free survival (PFS) compared to platinum-based chemotherapy. ZEGFROVY is positioned as a potential first chemo-free, oral therapy for this patient group. The results will be presented at an upcoming scientific congress, and Dizal plans to engage with regulatory authorities for potential new drug applications.

07:26 ETDizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

Dizal Pharmaceutical: Planning to issue H shares and list on the Hong Kong Stock Exchange

Wallstreetcn

According to the Zhitong Finance APP, Dizal Pharmaceutical disclosed its third-quarter report for 2025, stating that the company achieved revenue of 586 million yuan in the first three quarters, a year-on-year increase of 73.23%; the net profit attributable to the parent company was a loss of 580 million yuan; the net profit excluding non-recurring gains and losses was a loss of 631 million yuan; and the basic earnings per share were -1.32 yuan

Zhitong

Dizal Pharmaceutical released its performance for the first three quarters, with a net loss attributable to the parent company of 580 million yuan

688235

BGNE

06160

688062

002653

688180

01877

Guangfa Securities released a research report indicating that under the backdrop of innovation upgrading and internationalization, the domestic pharmaceutical industry is gradually shifting from following innovation to leading innovation, and it is expected to usher in a new round of investment opportunities in the product cycle in the medium to long term. In the first half of 2025, the pharmaceutical industry's operating revenue year-on-year growth rate was -2.3%, but profitability continued to improve. Among the 16 Hong Kong-listed pharmaceutical companies, 9 companies achieved positive growth in operating revenue, and 11 companies reported positive growth in net profit attributable to the parent company after deducting non-recurring gains and losses. Biotech companies saw a year-on-year revenue increase of 24.6%, mainly benefiting from the launch of new products and accelerated internationalization

BeOne Medicines

Beigene

BEONE MEDICINES

Mabwell

Haisco

Junshi Biosciences

JUNSHI BIO

Guangfa Securities: The long-term positive trend in the industry has been established; BD is just the starting point for the current round of innovative drug value reassessment

Dizal Pharmaceutical(688192.SH)